Current FDA-approved CAR-T cell therapies express CARs recognizing CD19, which is expressed on the surface of almost all B cells, making these therapies specific for B-cell malignancies.
Rebecca Bigler, PhD
Advertisement
Articles by Rebecca Bigler, PhD
Advertisement
Latest Updated Articles
CAR T-Cell Therapy: Genetically Programming the Immune System to Attack Malignant CellsPublished: February 25th 2020 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Axatilimab: A New Frontier for Steroid-Refractory Chronic GVHD
2
CHEST 2025: Exploring the Link Between GLP-1 Receptor Agonists, Type 2 Diabetes, and Asthma Risk
3
Immunization and Vigilance: Preventing Infections in T-Cell Modifying Therapies
4
World Standards Week 2025: Advancing Quality and Patient Safety Standards to Shape Pharmacy Practice and Innovation
5
